Dimensional Fund Advisors
TRDA icon

Dimensional Fund Advisors’s Entrada Therapeutics TRDA Stock Holding History

Dimensional Fund Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.09M Buy
324,471
+51,093
+19% +$586K ﹤0.01% 2557
2025
Q4 		$2.81M Sell
273,378
-120,901
-31% -$1.02M ﹤0.01% 2664
2025
Q3 		$2.29M Sell
394,279
-29,706
-7% -$174K ﹤0.01% 2738
2025
Q2 		$2.85M Buy
423,985
+96,858
+30% +$779K ﹤0.01% 2667
2025
Q1 		$2.96M Buy
327,127
+110,121
+51% +$1.37M ﹤0.01% 2627
2024
Q4 		$3.75M Buy
217,006
+121,598
+127% +$2.2M ﹤0.01% 2620
2024
Q3 		$1.53M Buy
+95,408
New +$1.5M ﹤0.01% 2840

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors's TRDA Position: Q1 2026 in Review

Dimensional Fund Advisors increased its Entrada Therapeutics (TRDA) stake by 19% in Q1 2026, buying an estimated $586K and bringing the position to 324,471 shares worth $4.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2557.

Dimensional Fund Advisors first reported a position in TRDA in Q3 2024 and has held it in 7 quarters since. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Dimensional Fund Advisors held 324,471 shares of Entrada Therapeutics worth $4.09M as of Q1 2026.
  • Dimensional Fund Advisors bought 51,093 Entrada Therapeutics shares in Q1 2026, an estimated $586K.
  • Entrada Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #2557 holding.
  • Dimensional Fund Advisors first reported a position in Entrada Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.